Gregory J. Riely, MD, PhD
Posted: Monday, June 10, 2019
What is your protocol when a patient with advanced NSCLC who is receiving dabrafenib/trametinib develops a grade 1 or 2 fever or higher?
JNCCN Spotlights
View More
Resources
For your Patients